Cargando…

The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes

OBJECTIVE: Basal insulin glargine has a neutral effect on cardiovascular risk in type 2 diabetes (T2DM). In practice, basal insulin is often paired with a glucagon-like peptide-1 receptor agonist (GLP1-RA) or meal insulin; however, the cardiovascular implications of these combinations have not been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Retnakaran, Ravi, Pu, Jiajie, Ye, Chang, Emery, Alexandra, Kramer, Caroline K., Zinman, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998007/ https://www.ncbi.nlm.nih.gov/pubmed/36894921 http://dx.doi.org/10.1186/s12933-023-01781-z

Ejemplares similares

The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial
por: Retnakaran, Ravi, et al.
Publicado: (2022)

Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2023)

Predictors of sustained drug-free diabetes remission over 48 weeks following short-term intensive insulin therapy in early type 2 diabetes
por: Kramer, Caroline K, et al.
Publicado: (2016)

Exenatide versus Insulin Lispro Added to Basal Insulin in a Subgroup of Korean Patients with Type 2 Diabetes Mellitus
por: Yoon, Kun-Ho, et al.
Publicado: (2017)

Predicting and understanding the response to short-term intensive insulin therapy in people with early type 2 diabetes
por: Nunez Lopez, Yury O., et al.
Publicado: (2018)

Hepatic Insulin Resistance Is an Early Determinant of Declining β-Cell Function in the First Year Postpartum After Glucose Intolerance in Pregnancy
por: Retnakaran, Ravi, et al.
Publicado: (2011)

A real‐world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672)
por: Stryker, Matthew D., et al.
Publicado: (2017)

Determinants of Insulin Resistance in Infants at Age 1 Year: Impact of gestational diabetes mellitus
por: Borgoño, Carla A., et al.
Publicado: (2012)

Changes Over Time in Glycemic Control, Insulin Sensitivity, and β-Cell Function in Response to Low-Dose Metformin and Thiazolidinedione Combination Therapy in Patients With Impaired Glucose Tolerance
por: Retnakaran, Ravi, et al.
Publicado: (2011)

Glucose Control and Weight Change Associated with Treatment with Exenatide Compared with Basal Insulin: A Retrospective Study
por: Morgan, Christopher Ll., et al.
Publicado: (2018)

Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study
por: Ponirakis, Georgios, et al.
Publicado: (2020)

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance
por: Du, Xuan, et al.
Publicado: (2018)

Determinants of longitudinal change in insulin clearance: the Prospective Metabolism and Islet Cell Evaluation cohort
por: Semnani-Azad, Zhila, et al.
Publicado: (2019)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
por: Tobin, G S, et al.
Publicado: (2012)

Relationship of body mass index with efficacy of exenatide twice daily added to insulin glargine in patients with type 2 diabetes
por: Wolffenbuttel, B. H. R., et al.
Publicado: (2016)

Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
por: Nasrallah, Sami N., et al.
Publicado: (2012)

Randomized Comparison of Pramlintide or Mealtime Insulin Added to Basal Insulin Treatment for Patients With Type 2 Diabetes
por: Riddle, Matthew, et al.
Publicado: (2009)

Association of Vitamin D With Insulin Resistance and β-Cell Dysfunction in Subjects at Risk for Type 2 Diabetes
por: Kayaniyil, Sheena, et al.
Publicado: (2010)

Concentrated insulins: the new basal insulins
por: Lamos, Elizabeth M, et al.
Publicado: (2016)

Tolerability and Effectiveness of Exenatide Once Weekly Relative to Basal Insulin Among Type 2 Diabetes Patients of Different Races in Routine Care
por: Nunes, Anthony P., et al.
Publicado: (2017)

The Impact of Adding Prandial Insulin to a Basal Based Regimen with Insulin Glargine in Type 2 Diabetic Patients
por: Khamseh, Mohammad Ebrahim, et al.
Publicado: (2021)

Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION‐7 randomized study
por: Guja, Cristian, et al.
Publicado: (2018)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
por: Ahmann, Andrew
Publicado: (2015)

Successful Treatment with Bedtime Basal Insulin Added to Metformin without Weight Gain or Hypoglycaemia over Three Years
por: Mertes, Bernardo, et al.
Publicado: (2020)

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE
por: Mathieu, Chantal, et al.
Publicado: (2013)

Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue
por: Bai, Chuanmin, et al.
Publicado: (2022)

Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011)

Endothelial Function in Women with and without a History of Glucose Intolerance in Pregnancy
por: Brewster, Shireen, et al.
Publicado: (2013)

Adding to the spectrum of insulin sensitive populations for mixed meal tolerance test glucose reliability assessment
por: Paglialunga, Sabina, et al.
Publicado: (2016)

Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial
por: Arakaki, R F, et al.
Publicado: (2014)

Pharmacokinetics and pharmacodynamics of insulin glargine–insulin glulisine basal-bolus and twice-daily premixed analog insulin in type 1 diabetes mellitus patients during three standardized meals
por: Lamos, Elizabeth Mary, et al.
Publicado: (2015)

Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
por: Rhinehart, Andrew S.
Publicado: (2015)

A Safe and Simple Algorithm for Adding and Adjusting Mealtime Insulin to Basal-Only Therapy
por: Johnson, Mary L., et al.
Publicado: (2022)

The GLP-1 Analogue Exenatide Improves Hepatic and Muscle Insulin Sensitivity in Diabetic Rats: Tracer Studies in the Basal State and during Hyperinsulinemic-Euglycemic Clamp
por: Wu, Hui, et al.
Publicado: (2014)

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
por: Rosenstock, J., et al.
Publicado: (2015)

Exenatide Treatment for 6 Months Improves Insulin Sensitivity in Adults With Type 1 Diabetes
por: Sarkar, Gayatri, et al.
Publicado: (2014)

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study
por: Kiiskinen, Urpo, et al.
Publicado: (2013)

Acute pharmacodynamic responses to exenatide: Drug-induced increases in insulin secretion and glucose effectiveness
por: Taylor, Simeon I., et al.
Publicado: (2023)

Insulin-like growth factor-2 regulates basal retinal insulin receptor activity
por: Zolov, Sergey N., et al.
Publicado: (2021)

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes
por: Rosenstock, Julio, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9e9ubjdi8c4nkiedfqf5fs94eu